about
Adherence to multiple medications prescribed for a chronic disease: a methodological investigation.Medication adherence among recipients with chronic diseases enrolled in a state Medicaid program.Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer.Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States.Ascertainment of postprostatectomy radiotherapy for prostate cancer in the Surveillance, Epidemiology, and End Results database.Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.Hospital pharmacists' perceived beliefs and responsibilities in indication-based off-label prescribing.Aggressive End-of-Life Care for Metastatic Cancer Patients Younger Than Age 65 Years.Prostate Cancer Patient Characteristics Associated With a Strong Preference to Preserve Sexual Function and Receipt of Active Surveillance.Comparing algorithms for composite measures of intra-disease multiple medication adherence: The case of diabetesThe role of perceived impact on relationship quality in pharmacists' willingness to influence indication-based off-label prescribing decisionsAndrogen Deprivation Therapy and Dose-Escalated Radiotherapy for Intermediate- and High-Risk Prostate Cancer-ReplyFactors influencing prostate cancer treatment decisions for African American and white menTotal Medicare Costs Associated With Diagnosis and Treatment of Prostate Cancer in Elderly MenPatient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer
P50
Q38233934-F4FFA4AE-FAF6-421A-BDFC-4F2EE6237B4EQ38434001-B9FBBE2C-6DF5-4189-AE72-5C9482510D35Q38890089-B072C038-2C2B-44D6-BED9-17418DFE6269Q39639348-EE4DE039-FFE6-4426-B4B6-F7381476D904Q39648805-C06BFFEB-BEA3-45F0-9DEF-61A9E7D6BD29Q39756984-A30EAA93-38DC-405D-B720-B6C06FA3E0C4Q39772182-803B7685-6732-4CAF-9A60-E90D1E878E53Q40364849-AEEAA6DE-56A5-4FF3-BD21-336224033DA2Q47369271-C464FB80-8549-4337-A2DF-E4B63ABFA4D7Q49716886-EFA391BC-3897-4C05-B35A-8CF22709C1F7Q50089850-1A016C3F-AB38-4D92-A1D5-2236FF6CFA4EQ57298320-0A58FBBC-4BE4-4388-8044-B29E72153E02Q87011580-D8571E74-E8DD-4482-8A58-14483F6D4CC2Q88851358-123DB72D-C5C5-40CF-9043-D33C2984AE6CQ91267187-443A038E-85DE-4299-ACDB-9037941B67ACQ91641234-9E5196EC-9FB1-4D49-B234-397F9FBBBF7AQ92279457-40525095-13F5-4EB9-83D5-E024D6E10B13
P50
description
researcher ORCID ID = 0000-0001-6665-0370
@en
wetenschapper
@nl
name
Ramsankar Basak
@ast
Ramsankar Basak
@en
Ramsankar Basak
@es
Ramsankar Basak
@nl
type
label
Ramsankar Basak
@ast
Ramsankar Basak
@en
Ramsankar Basak
@es
Ramsankar Basak
@nl
prefLabel
Ramsankar Basak
@ast
Ramsankar Basak
@en
Ramsankar Basak
@es
Ramsankar Basak
@nl
P106
P31
P496
0000-0001-6665-0370